Cargando…
Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial
AIMS/INTRODUCTION: Metformin is associated with the risk of gastrointestinal complications, and probiotic Bifidobacterium bifidum G9‐1 (BBG9‐1) can improve the symptoms of diarrhea. This study aimed to clarify the effects of probiotic BBG9‐1 on the gastrointestinal symptoms of type 2 diabetes mellit...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902400/ https://www.ncbi.nlm.nih.gov/pubmed/34665938 http://dx.doi.org/10.1111/jdi.13698 |
_version_ | 1784664591464136704 |
---|---|
author | Hata, Shinnosuke Nakajima, Hanako Hashimoto, Yoshitaka Miyoshi, Tomoki Hosomi, Yukako Okamura, Takuro Majima, Saori Nakanishi, Naoko Senmaru, Takafumi Osaka, Takafumi Okada, Hiroshi Ushigome, Emi Hamaguchi, Masahide Asano, Mai Yamazaki, Masahiro Fukui, Michiaki |
author_facet | Hata, Shinnosuke Nakajima, Hanako Hashimoto, Yoshitaka Miyoshi, Tomoki Hosomi, Yukako Okamura, Takuro Majima, Saori Nakanishi, Naoko Senmaru, Takafumi Osaka, Takafumi Okada, Hiroshi Ushigome, Emi Hamaguchi, Masahide Asano, Mai Yamazaki, Masahiro Fukui, Michiaki |
author_sort | Hata, Shinnosuke |
collection | PubMed |
description | AIMS/INTRODUCTION: Metformin is associated with the risk of gastrointestinal complications, and probiotic Bifidobacterium bifidum G9‐1 (BBG9‐1) can improve the symptoms of diarrhea. This study aimed to clarify the effects of probiotic BBG9‐1 on the gastrointestinal symptoms of type 2 diabetes mellitus patients using metformin. MATERIALS AND METHODS: In this open‐label single‐arm exploratory study, 40 patients (mean age 64.0 ± 9.4 years) were given probiotic BBG9‐1 for 10 weeks. Changes in the gastrointestinal symptom rating scale total score, which was the primary end‐point, gastrointestinal symptom rating scale subscale scores, glycated hemoglobin levels and gut microbiota after the administration of probiotic BBG9‐1 were evaluated by the Student's t‐test. RESULTS: The gastrointestinal symptom rating scale total score significantly improved (from 2.02 ± 0.51 to 1.59 ± 0.43, change, −0.43 ± 0.49, P < 0.001). Furthermore, all gastrointestinal symptom rating scale subscale scores, including diarrhea (from 2.32 ± 1.14 to 1.89 ± 0.99, change, −0.42 ± 0.95, P = 0.007) and constipation (from 3.00 ± 1.16 to 2.20 ± 1.07, change, −0.80 ± 1.19, P < 0.001), scores also significantly improved. However, the glycated hemoglobin levels did not change (from 7.0 ± 0.7 to 7.0 ± 0.6%, change, 0.0 ± 0.4, P = 0.91). The relative abundance of the genus Sutterella decreased by the use of probiotic BBG9‐1 (from 0.011 ± 0.009 to 0.008 ± 0.006, change, −0.003 ± 0.006, P = 0.002). CONCLUSIONS: Type 2 diabetes mellitus patients treated with metformin showed significant improvement in all gastrointestinal symptom rating scores after using probiotic BBG9‐1 without changing the glucose control. This study showed the potential usefulness of probiotic BBG9‐1 for improving gastrointestinal symptoms, including constipation and diarrhea, in type 2 diabetes mellitus patients treated with metformin. |
format | Online Article Text |
id | pubmed-8902400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89024002022-03-11 Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial Hata, Shinnosuke Nakajima, Hanako Hashimoto, Yoshitaka Miyoshi, Tomoki Hosomi, Yukako Okamura, Takuro Majima, Saori Nakanishi, Naoko Senmaru, Takafumi Osaka, Takafumi Okada, Hiroshi Ushigome, Emi Hamaguchi, Masahide Asano, Mai Yamazaki, Masahiro Fukui, Michiaki J Diabetes Investig Articles AIMS/INTRODUCTION: Metformin is associated with the risk of gastrointestinal complications, and probiotic Bifidobacterium bifidum G9‐1 (BBG9‐1) can improve the symptoms of diarrhea. This study aimed to clarify the effects of probiotic BBG9‐1 on the gastrointestinal symptoms of type 2 diabetes mellitus patients using metformin. MATERIALS AND METHODS: In this open‐label single‐arm exploratory study, 40 patients (mean age 64.0 ± 9.4 years) were given probiotic BBG9‐1 for 10 weeks. Changes in the gastrointestinal symptom rating scale total score, which was the primary end‐point, gastrointestinal symptom rating scale subscale scores, glycated hemoglobin levels and gut microbiota after the administration of probiotic BBG9‐1 were evaluated by the Student's t‐test. RESULTS: The gastrointestinal symptom rating scale total score significantly improved (from 2.02 ± 0.51 to 1.59 ± 0.43, change, −0.43 ± 0.49, P < 0.001). Furthermore, all gastrointestinal symptom rating scale subscale scores, including diarrhea (from 2.32 ± 1.14 to 1.89 ± 0.99, change, −0.42 ± 0.95, P = 0.007) and constipation (from 3.00 ± 1.16 to 2.20 ± 1.07, change, −0.80 ± 1.19, P < 0.001), scores also significantly improved. However, the glycated hemoglobin levels did not change (from 7.0 ± 0.7 to 7.0 ± 0.6%, change, 0.0 ± 0.4, P = 0.91). The relative abundance of the genus Sutterella decreased by the use of probiotic BBG9‐1 (from 0.011 ± 0.009 to 0.008 ± 0.006, change, −0.003 ± 0.006, P = 0.002). CONCLUSIONS: Type 2 diabetes mellitus patients treated with metformin showed significant improvement in all gastrointestinal symptom rating scores after using probiotic BBG9‐1 without changing the glucose control. This study showed the potential usefulness of probiotic BBG9‐1 for improving gastrointestinal symptoms, including constipation and diarrhea, in type 2 diabetes mellitus patients treated with metformin. John Wiley and Sons Inc. 2021-11-15 2022-03 /pmc/articles/PMC8902400/ /pubmed/34665938 http://dx.doi.org/10.1111/jdi.13698 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Hata, Shinnosuke Nakajima, Hanako Hashimoto, Yoshitaka Miyoshi, Tomoki Hosomi, Yukako Okamura, Takuro Majima, Saori Nakanishi, Naoko Senmaru, Takafumi Osaka, Takafumi Okada, Hiroshi Ushigome, Emi Hamaguchi, Masahide Asano, Mai Yamazaki, Masahiro Fukui, Michiaki Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial |
title | Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial |
title_full | Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial |
title_fullStr | Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial |
title_full_unstemmed | Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial |
title_short | Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial |
title_sort | effects of probiotic bifidobacterium bifidum g9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: an open‐label, single‐arm, exploratory research trial |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902400/ https://www.ncbi.nlm.nih.gov/pubmed/34665938 http://dx.doi.org/10.1111/jdi.13698 |
work_keys_str_mv | AT hatashinnosuke effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT nakajimahanako effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT hashimotoyoshitaka effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT miyoshitomoki effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT hosomiyukako effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT okamuratakuro effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT majimasaori effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT nakanishinaoko effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT senmarutakafumi effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT osakatakafumi effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT okadahiroshi effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT ushigomeemi effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT hamaguchimasahide effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT asanomai effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT yamazakimasahiro effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial AT fukuimichiaki effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial |